{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:28:09Z","timestamp":1790926089292,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2001,10,1]]},"DOI":"10.1038\/sj.bmt.1703207","type":"journal-article","created":{"date-parts":[[2002,9,17]],"date-time":"2002-09-17T16:39:08Z","timestamp":1032280748000},"page":"743-751","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":130,"title":["Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens"],"prefix":"10.1038","volume":"28","author":[{"given":"N","family":"Bleyzac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Souillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Magron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Janoly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Galambrun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Maire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RW","family":"Jelliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Aulagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2001,11,22]]},"reference":[{"key":"BF1703207_CR1","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1182\/blood.V64.4.852.852","volume":"64","author":"R Parkman","year":"1984","unstructured":"Parkman R, Rappeport JM, Hellman S et al. Busulfan and total body irradiation as anti-haemopoietic stem cell agents in the preparation of patients with congenital bone marrow disorders for allogeneic bone marrow transplantation Blood 1984 64: 852\u2013857","journal-title":"Blood"},{"key":"BF1703207_CR2","first-page":"171","volume":"18","author":"MJ Styler","year":"1996","unstructured":"Styler MJ, Crilley P, Biggs J et al. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis Bone Marrow Transplant 1996 18: 171\u2013176","journal-title":"Bone Marrow Transplant"},{"key":"BF1703207_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/sj.bmt.1700985","volume":"20","author":"JD Morris","year":"1997","unstructured":"Morris JD, Harris RE, Hashmi R et al. Antithrombine III for the treatment of chemotherapy induced organ dysfunction following bone marrow transplantation Bone Marrow Transplant 1997 20: 871\u2013878","journal-title":"Bone Marrow Transplant"},{"key":"BF1703207_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/sj.bmt.1701334","volume":"22","author":"AR Hartman","year":"1998","unstructured":"Hartman AR, Williams SF, Dillon JJ . Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan\/cyclophosphamide versus total body irradiation: a meta-analysis Bone Marrow Transplant 1998 22: 439\u2013443","journal-title":"Bone Marrow Transplant"},{"key":"BF1703207_CR5","first-page":"1249","volume":"31","author":"SA Comcowich","year":"1997","unstructured":"Comcowich SA, Spitzer TR, Tsunoda SM . Ursodiol to prevent hepatic veno-occlusive disease Ann Pharmacother 1997 31: 1249\u20131252","journal-title":"Ann Pharmacother"},{"key":"BF1703207_CR6","first-page":"75","volume":"17","author":"C Rozman","year":"1996","unstructured":"Rozman C, Carreras E, Qian C et al. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia Bone Marrow Transplant 1996 17: 75\u201380","journal-title":"Bone Marrow Transplant"},{"key":"BF1703207_CR7","first-page":"1","volume":"13","author":"TP Baglin","year":"1994","unstructured":"Baglin TP . Veno-occlusive disease of the liver complicating bone marrow transplantation Bone Marrow Transplant 1994 13: 1\u20134","journal-title":"Bone Marrow Transplant"},{"key":"BF1703207_CR8","first-page":"31","volume":"16","author":"JT Slattery","year":"1995","unstructured":"Slattery JT, Sanders JE, Buckner CD et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics Bone Marrow Transplant 1995 16: 31\u201342","journal-title":"Bone Marrow Transplant"},{"key":"BF1703207_CR9","first-page":"225","volume":"17","author":"SP Dix","year":"1996","unstructured":"Dix SP, Wingard JR, Mullins RE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT Bone Marrow Transplant 1996 17: 225\u2013230","journal-title":"Bone Marrow Transplant"},{"key":"BF1703207_CR10","first-page":"843","volume":"18","author":"M Hassan","year":"1996","unstructured":"Hassan M, Fasth A, Gerritsen B et al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders Bone Marrow Transplant 1996 18: 843\u2013850","journal-title":"Bone Marrow Transplant"},{"key":"BF1703207_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/sj.bmt.1700891","volume":"20","author":"DS Chattergoon","year":"1997","unstructured":"Chattergoon DS, Saunders EF, Klein J et al. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children Bone Marrow Transplant 1997 20: 347\u2013354","journal-title":"Bone Marrow Transplant"},{"key":"BF1703207_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/00007691-199810000-00017","volume":"20","author":"JT Slattery","year":"1998","unstructured":"Slattery JT, Risler LJ . Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation Ther Drug Monit 1998 20: 543\u2013554","journal-title":"Ther Drug Monit"},{"key":"BF1703207_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/BF00694339","volume":"25","author":"LB Grochow","year":"1989","unstructured":"Grochow LB, Jones RJ, Brundrett RB . Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation Cancer Chemother Pharmacol 1989 25: 55\u201361","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF1703207_CR14","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/sj.bmt.1702561","volume":"26","author":"HT Tran","year":"2000","unstructured":"Tran HT, Madden T, Petropoulos D et al. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies Bone Marrow Transplant 2000 26: 463\u2013470","journal-title":"Bone Marrow Transplant"},{"key":"BF1703207_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/BF00689702","volume":"28","author":"M Hassan","year":"1991","unstructured":"Hassan M, Oberg G, Bekassy AN et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology Cancer Chemother Pharmacol 1991 28: 130\u2013134","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF1703207_CR16","first-page":"3678","volume":"56","author":"JP Gibbs","year":"1996","unstructured":"Gibbs JP, Murray G, Risler L et al. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan Cancer Res 1996 56: 3678\u20133681","journal-title":"Cancer Res"},{"key":"BF1703207_CR17","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood.V79.9.2475.2475","volume":"79","author":"G Vassal","year":"1992","unstructured":"Vassal G, Deroussent A, Challine D et al. Is 600 mg\/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 1992 79: 2475\u20132479","journal-title":"Blood"},{"key":"BF1703207_CR18","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/00007691-199310000-00005","volume":"15","author":"RW Jelliffe","year":"1993","unstructured":"Jelliffe RW, Schumitzky A, Van Guilder M et al. Individualizing drug dosage regimens: roles of population and pharmacodynamic models, bayesian fitting, and adaptive control Ther Drug Monit 1993 15: 380\u2013393","journal-title":"Ther Drug Monit"},{"key":"BF1703207_CR19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0378-4347(00)00167-5","volume":"742","author":"N Bleyzac","year":"2000","unstructured":"Bleyzac N, Barou P, Aulagner G . Rapid and sensitive high-performace liquid chromatographic method for busulfan assay in plasma J Chromatogr Biomed Appl 2000 742: 427\u2013432","journal-title":"J Chromatogr Biomed Appl"},{"key":"BF1703207_CR20","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/BF01070904","volume":"9","author":"DZ D'Argenio","year":"1981","unstructured":"D'Argenio DZ . Optimal sampling times for pharmacokinetic experiments J Pharmacokin Biopharm 1981 9: 739\u2013756","journal-title":"J Pharmacokin Biopharm"},{"key":"BF1703207_CR21","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1023\/A:1020703007613","volume":"26","author":"M Tod","year":"1998","unstructured":"Tod M, Mentre F, Merle Y, Mallet A . Robust design for the estimation on hyperparameters in population pharmacokinetics J Pharmacokin Biopharm 1998 26: 689\u2013711","journal-title":"J Pharmacokin Biopharm"},{"key":"BF1703207_CR22","unstructured":"Laboratory of Applied Pharmacokinetics. USC*Pack P.C. Collection Clinical Research Programs, Los Angeles. University of Southern California, School of Medicine, 1995, version 10.7"},{"key":"BF1703207_CR23","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/00007691-199910000-00005","volume":"21","author":"N Bleyzac","year":"1999","unstructured":"Bleyzac N, Barou P, Massenavette B et al. Assessment of acyclovir intraindividual pharmacokinetic variability during continuous hemofiltration, continuous hemodiafiltration and continuous hemodialysis Ther Drug Monit 1999 21: 520\u2013525","journal-title":"Ther Drug Monit"},{"key":"BF1703207_CR24","doi-asserted-by":"publisher","first-page":"10953","DOI":"10.1093\/nar\/16.23.10953","volume":"16","author":"AJ Jeffreys","year":"1988","unstructured":"Jeffreys AJ, Wilson W, Neimann R, Keyte J . Amplification of human minisatellites by the PCR: toward fingerprinting of single cells Nucleic Acid Res 1988 16: 10953\u201310971","journal-title":"Nucleic Acid Res"},{"key":"BF1703207_CR25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/sj.bmt.1702590","volume":"26","author":"KS Baker","year":"2000","unstructured":"Baker KS, Bostrom B, DeFor T et al. Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia Bone Marrow Transplant 2000 26: 607\u2013614","journal-title":"Bone Marrow Transplant"},{"key":"BF1703207_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/sj.bmt.1701584","volume":"23","author":"CK Li","year":"1999","unstructured":"Li CK, Yuen PMP, Wong R et al. Busulphan level and early mortality in thalassemia patients after BMT Bone Marrow Transplant 1999 23: 307\u2013310","journal-title":"Bone Marrow Transplant"},{"key":"BF1703207_CR27","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/sj.bmt.1702371","volume":"25","author":"AM Bolinger","year":"2000","unstructured":"Bolinger AM, Zangwill AB, Slattery JT et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease Bone Marrow Transplant 2000 25: 925\u2013930","journal-title":"Bone Marrow Transplant"},{"key":"BF1703207_CR28","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1203\/00006450-199905010-00187","volume":"45","author":"P Magron","year":"1999","unstructured":"Magron P, Bleyzac N, Souillet G et al. Control of intra- and inter-patient variability by Bayesian forecasting of busulfan dosage regimens in pediatric BMT Pediat Res 1999 45: 769 (Abstr.)","journal-title":"Pediat Res"},{"key":"BF1703207_CR29","volume-title":"IVIG prophylaxis in allogeneic sibling SCT: preliminary results of a randomized dose-effect, placebo-controlled, double-blind, multicenter trial","author":"C Cordonnier","year":"2001","unstructured":"Cordonnier C, Chevret S, Legrand M et al. IVIG prophylaxis in allogeneic sibling SCT: preliminary results of a randomized dose-effect, placebo-controlled, double-blind, multicenter trial 27th Annual Meeting of European Group for Blood and Marrow Transplantation, Maastricht 2001"},{"key":"BF1703207_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/sj.bmt.1702504","volume":"26","author":"SJ Choi","year":"2000","unstructured":"Choi SJ, Lee KH, Lee JH et al. Prognostic value of hematopoietic chimerism in patients with acute leukemia after allogeneic bone marrow transplantation: a prospective study Bone Marrow Transplant 2000 26: 327\u2013332","journal-title":"Bone Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1703207","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703207.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703207.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T22:05:58Z","timestamp":1648073158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1703207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10,1]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2001,10,1]]}},"alternative-id":["BF1703207"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1703207","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,10,1]]},"assertion":[{"value":"31 January 2001","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2001","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2001","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}